Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

In a report released today, Maury Raycroft from Jefferies maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), ...

The venture capital firm Atlas Venture is launching a start-up that aims to develop antisense oligonucleotides for a ...

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company's launch and $100 million in initial financing, including seed financing and ...

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

Global Lipid Nanoparticles Market was valued at US$ 820.51 million in 2023 and is projected to hit the market valuation of US$ 2,387.98 million by 2032 at a CAGR of 12.6% during the forecast period ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge's ...

Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits ...

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.